Bright Minds Biosciences Inc (DRUG)

Jan 26, 2025, 6:32 AM EST - 2 months ago

Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101

Jan 7, 2025, 6:50 AM EST - 3 months ago

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Nov 4, 2024, 2:41 PM EST - 5 months ago

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Oct 30, 2024, 1:07 AM EDT - 5 months ago

Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential

Oct 28, 2024, 8:21 AM EDT - 5 months ago

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update

NVCT

Oct 21, 2024, 8:30 AM EDT - 5 months ago

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Oct 18, 2024, 6:50 AM EDT - 6 months ago

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Oct 16, 2024, 10:45 AM EDT - 6 months ago

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Oct 15, 2024, 9:09 PM EDT - 6 months ago

Bright Minds is Unaware of Any Material Changes

Oct 3, 2024, 9:00 AM EDT - 6 months ago

Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events

Sep 19, 2024, 10:00 AM EDT - 7 months ago

Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th

Sep 12, 2024, 8:00 AM EDT - 7 months ago

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Aug 8, 2023, 6:50 AM EDT - 1 year ago

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 20, 2023, 6:50 AM EDT - 1 year ago

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Jul 12, 2023, 10:33 AM EDT - 1 year ago

CSE Bulletin: Consolidation - Bright Minds Biosciences Inc. (DRUG)

Jul 11, 2023, 6:50 AM EDT - 1 year ago

Bright Minds Announces Effective Date of Share Consolidation

Jun 22, 2023, 6:50 AM EDT - 1 year ago

Bright Minds Announces Proposed Share Consolidation

Apr 19, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Apr 10, 2023, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Feb 27, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Feb 17, 2023, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Announces Non-Executive Director Appointment

Feb 8, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Deficiency Letter Regarding Independent Director and Audit Committee Requirements

Jan 27, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Jan 9, 2023, 4:05 PM EST - 2 years ago

Bright Minds Biosciences Announces Resignation of Board Member

Dec 2, 2022, 7:07 PM EST - 2 years ago

Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement

Nov 28, 2022, 6:50 AM EST - 2 years ago

Bright Minds Biosciences Announces Non-Brokered Private Placement

Nov 23, 2022, 11:35 AM EST - 2 years ago

Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D.

Sep 7, 2022, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

Aug 31, 2022, 6:50 AM EDT - 2 years ago

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

Aug 30, 2022, 3:35 PM EDT - 2 years ago

Bright Minds Biosciences Announces Closing of $4 Million Unit Offering

Aug 23, 2022, 9:07 PM EDT - 2 years ago

Bright Minds Announces Pricing of Overnight Marketed Offering of Units

Aug 22, 2022, 7:05 PM EDT - 2 years ago

Bright Minds Announces Overnight Marketed Offering of Units

Aug 18, 2022, 3:34 PM EDT - 2 years ago

Bright Minds Biosciences Comments on Recent Trading Activity

Jun 27, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization

May 12, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

May 2, 2022, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties

Nov 30, 2021, 7:30 AM EST - 3 years ago

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Nov 4, 2021, 8:52 AM EDT - 3 years ago

Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Nov 3, 2021, 6:50 AM EDT - 3 years ago

Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG”